Abstract
The US Preventive Services Task Force cholesterol guideline recommended statins for fewer adults than the 2013 American College of Cardiology/American Heart Association (ACC/AHA) guideline by setting a higher 10-year atherosclerotic cardiovascular disease threshold (≥10.0% vs ≥7.5%) and requiring concomitant diabetes mellitus, hypertension, dyslipidemia, or cigarette smoking. The 2017 ACC/AHA hypertension guideline lowered the hypertension threshold, increasing 2016 guideline statin-eligible adults. Cross-sectional data on US adults aged 40 to 75 years enabled estimated numbers for the 2013 guideline and 2016 guideline with hypertension thresholds of ≥140/≥90 mm Hg and ≥130/80 mm Hg, respectively, on: (1) untreated, statin-eligible adults for primary atherosclerotic cardiovascular disease prevention (25.40, 14.72, 15.35 million); (2) atherosclerotic cardiovascular disease events prevented annually (124 000, 70 852, 73 199); (3) number needed to treat (21, 21, 21); and (4) number needed to harm (38, 143, 143) per 1000 patient-years for incident diabetes mellitus (42 800, 6700, 7100 cases per year). Despite the lower hypertension threshold, the 2013 cholesterol guideline qualifies approximately 10 million more adults for statins ...Continue Reading
References
Apr 11, 2003·Lancet·Peter S SeverUNKNOWN ASCOT investigators
Nov 11, 2008·The New England Journal of Medicine·Paul M RidkerUNKNOWN JUPITER Study Group
Jan 6, 2010·Circulation·Kwan Leung ChanUNKNOWN ASTRONOMER Investigators
Feb 20, 2010·Lancet·Naveed SattarIan Ford
Mar 27, 2010·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Andrew S Levey, Lesley A Stevens
Nov 12, 2010·Lancet·UNKNOWN Cholesterol Treatment Trialists’ (CTT) CollaborationR Collins
Jan 25, 2011·Cardiology Clinics·Joel A Lardizabal, Prakash Deedwania
Mar 10, 2011·European Heart Journal·Edward J MillsMatthias Briel
Jun 23, 2011·JAMA : the Journal of the American Medical Association·David PreissKausik K Ray
Mar 8, 2012·Circulation. Cardiovascular Quality and Outcomes·Joshua I BarzilayUNKNOWN ALLHAT Collaborative Research Group
May 23, 2012·Lancet·UNKNOWN Cholesterol Treatment Trialists' (CTT) CollaboratorsC Baigent
Aug 14, 2012·Lancet·Paul M RidkerRobert J Glynn
Mar 5, 2013·Current Diabetes Reports·Mark R Goldstein, Luca Mascitelli
Jul 3, 2013·Circulation·Brent M EganTamara E Wolfman
Jul 12, 2013·JAMA : the Journal of the American Medical Association·Christopher J L MurrayUNKNOWN U.S. Burden of Disease Collaborators
Nov 14, 2013·Circulation·Neil J StoneUNKNOWN American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Mar 22, 2014·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Lesley A InkerHarold I Feldman
May 31, 2014·BMJ : British Medical Journal·Colin R DormuthUNKNOWN Canadian Network for Observational Drug Effect Studies Investigators
Jun 23, 2015·Annals of Internal Medicine·John R Downs, Patrick G O'Malley
Jul 15, 2015·JAMA : the Journal of the American Medical Association·Ankur PandyaThomas A Gaziano
Nov 4, 2015·JAMA : the Journal of the American Medical Association·Elizabeth D KantorEdward L Giovannucci
May 22, 2016·Journal of Clinical Lipidology·Rishi K WadheraJoAnne M Foody
Aug 21, 2016·Journal of the American Heart Association·Brent M EganAngelo Sinopoli
Nov 14, 2016·JAMA : the Journal of the American Medical Association·UNKNOWN US Preventive Services Task ForceMichael P Pignone
Jan 11, 2017·Scientific Reports·Shaohua WangXiong Z Ruan
Apr 19, 2017·JAMA : the Journal of the American Medical Association·Neha J PagidipatiMichael J Pencina
Aug 12, 2017·The American Journal of Cardiology·Yogita RochlaniJawahar L Mehta
Nov 15, 2017·Hypertension·Paul K WheltonJackson T Wright